18 June 2018 - Almost half of diabetics are cutting back on treatment because of costs, according to a new survey that comes as the skyrocketing price of insulin is prompting lawmakers and physicians to call for more oversight.
The American Medical Association, the largest association of physicians in the U.S., last week called for federal intervention to protect diabetics from being exploited by price gouging on insulin products. The group wants the Federal Trade Commission and the Justice Department to track insulin pricing and market competition to protect consumers.
"It is shocking and unconscionable" that patients are struggling to get a basic medicine like insulin, AMA board member William A. McDade said in a statement.